CN116744928A - 调节serca的喹啉及其治疗疾病的用途 - Google Patents

调节serca的喹啉及其治疗疾病的用途 Download PDF

Info

Publication number
CN116744928A
CN116744928A CN202180063849.1A CN202180063849A CN116744928A CN 116744928 A CN116744928 A CN 116744928A CN 202180063849 A CN202180063849 A CN 202180063849A CN 116744928 A CN116744928 A CN 116744928A
Authority
CN
China
Prior art keywords
mmol
mixture
compound
water
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180063849.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuron Co
Original Assignee
Neuron Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by Neuron Co filed Critical Neuron Co
Publication of CN116744928A publication Critical patent/CN116744928A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180063849.1A 2020-07-20 2021-07-19 调节serca的喹啉及其治疗疾病的用途 Pending CN116744928A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease
US16/932,832 2020-07-20
PCT/US2021/042235 WO2022020261A1 (en) 2020-07-20 2021-07-19 Quinolines that modulate serca and their use for treating disease

Publications (1)

Publication Number Publication Date
CN116744928A true CN116744928A (zh) 2023-09-12

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063849.1A Pending CN116744928A (zh) 2020-07-20 2021-07-19 调节serca的喹啉及其治疗疾病的用途

Country Status (11)

Country Link
EP (1) EP4037685B9 (enExample)
JP (1) JP7705445B2 (enExample)
CN (1) CN116744928A (enExample)
CA (1) CA3186668A1 (enExample)
DK (1) DK4037685T3 (enExample)
ES (1) ES2968041T3 (enExample)
FI (1) FI4037685T3 (enExample)
HU (1) HUE064550T2 (enExample)
PL (1) PL4037685T3 (enExample)
PT (1) PT4037685T (enExample)
WO (1) WO2022020261A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2016032569A1 (en) * 2014-08-29 2016-03-03 Celladon Corporation Quinolines and their use for treating endoplasmic reticulum stress-caused diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
US10772881B2 (en) * 2017-02-27 2020-09-15 Russell Dahl Quinolines that modulate SERCA and their use for treating disease
US20200347038A1 (en) * 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑（2‑甲基‑8‑喹啉基）苯甲酰胺的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2016032569A1 (en) * 2014-08-29 2016-03-03 Celladon Corporation Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATHERINE KRAJNAK等: "A new target for Alzheimer\'s disease: A small molecule SEARCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice", 《BIOORG MED CHEM LETT.》, vol. 28, no. 9, 15 May 2018 (2018-05-15), pages 1591 - 1594 *
张雪;张雯;杜立达;高丽;杜冠华;: "抗帕金森病药物及其作用靶点研究进展", 国际药学研究杂志, no. 01, 29 February 2016 (2016-02-29), pages 95 - 104 *

Also Published As

Publication number Publication date
WO2022020261A1 (en) 2022-01-27
JP7705445B2 (ja) 2025-07-09
FI4037685T3 (fi) 2023-11-27
EP4037685A4 (en) 2022-11-30
DK4037685T3 (en) 2024-01-02
EP4037685B1 (en) 2023-09-20
WO2022020261A9 (en) 2022-09-09
CA3186668A1 (en) 2022-01-27
ES2968041T3 (es) 2024-05-06
PT4037685T (pt) 2023-12-28
HUE064550T2 (hu) 2024-03-28
EP4037685B9 (en) 2024-03-06
PL4037685T3 (pl) 2024-04-02
JP2023534992A (ja) 2023-08-15
EP4037685A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US12144806B2 (en) Quinolines that modulate SERCA and their use for treating disease
EP3174859A1 (en) Flt3 receptor antagonists
KR101471999B1 (ko) Ｇｓｋ-3 저해제
CA2788782A1 (en) Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20170281611A1 (en) Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
WO2016210289A1 (en) Chemical modulators of signaling pathways and therapeutic use
JP7642859B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物
JP2017537948A (ja) Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
CA3099018A1 (en) Rip1 inhibitory compounds and methods for making and using the same
CN107743483A (zh) Nadph氧化酶4抑制剂
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
US11827626B2 (en) Quinolines that modulate SERCA and their use for treating disease
US10772881B2 (en) Quinolines that modulate SERCA and their use for treating disease
US10383867B2 (en) Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
WO2016168524A1 (en) Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions
US10383868B2 (en) Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
EP4037685B1 (en) Quinoline that modulate serca and its use for treating disease
CN106420754B (zh) 苯并五元氮杂环基哌嗪衍生物的用途
CN112533917A (zh) 作为vps34的抑制剂的吗啉衍生物
HK40099648A (en) Quinolines that modulate serca and their use for treating disease
BRPI0619282A2 (pt) sal de p-toluenossulfonato, sal, composição farmacêutica, método de modular ppar e uso de um sal
KR101446738B1 (ko) 4-티오피라졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상지질혈증의 예방 또는 치료용 약학적 조성물
HK40125827A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
HK40055242A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099648

Country of ref document: HK